Glucose-Dependent Insulinotropic Polypeptide

Cited by (351)

Items 101–200 of 351

1. Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’
   Marius Skow, Natasha Chidekel Bergmann, Filip Krag Knop · 2016 · Diabetes Obesity and Metabolism
2. Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
   Zhou, Qian, Lei, Xingxing, Fu, Shunlian, Liu, Pan, Long, Cong, Wang, Yanmei, Li, Zinan, Xie, Qian, Chen, Qiu · 2023 · Diabetology & Metabolic Syndrome
3. Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long‐term impairment of the GIP system
   Maria Buur Nordskov Gabe, Wijnand J. C. van der Velden, Sarina Gadgaard, Florent Xavier Smit, Bolette Hartmann, Hans Bräuner‐Osborne, METTE MARIE ROSENKILDE · 2019 · Basic & Clinical Pharmacology & Toxicology
4. Loss of Function Glucose-Dependent Insulinotropic Polypeptide Receptor Variants Are Associated With Alterations in BMI, Bone Strength and Cardiovascular Outcomes
   Kizilkaya, Hüsün Sheyma, Sørensen, Kimmie Vestergaard, Kibsgaard, Camilla J., Gasbjerg, Laerke Smidt, Hauser, Alexander S., Sparre-Ulrich, Alexander Hovard, Grarup, Niels, Rosenkilde, Mette M. · 2021 · Frontiers in Cell and Developmental Biology
5. GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis
   Singh, Anmol, Sohal, Aalam, Batta, Akash · 2024 · World Journal of Gastroenterology
6. Hormonal Gut–Brain Signaling for the Treatment of Obesity
   Eun Roh, Kyung Mook Choi · 2023 · International Journal of Molecular Sciences
7. GIP analogues and the treatment of obesity-diabetes
   Clifford J. Bailey · 2019 · Peptides
8. Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme‐linked immunosorbent assay
   Toshihiro Matsuo, Jun‐ichiro Miyagawa, Yoshiki Kusunoki, Masayuki Miuchi, Takashi Ikawa, Takafumi Akagami, Masaru Tokuda, Tomoyuki Katsuno, Akira Kushida, Takashi Inagaki et al. · 2015 · Journal of Diabetes Investigation
9. Glucagon dynamics during hypoglycaemia and food‐re‐challenge following treatment with vildagliptin in insulin‐treated patients with type 2 diabetes
   Johan Farngren, Margaretha Persson, Anja Schweizer, James Edward Foley, Bo Åhrén · 2014 · Diabetes Obesity and Metabolism
10. SGLT2 inhibition and glucagon secretion in humans
    Chiara Saponaro, François N. Pattou, Caroline Bonner · 2018 · Diabetes & Metabolism
11. Glucagon, GLP-1 and Thermogenesis
    González-García, Ismael, Milbank, Edward, Diéguez, Carlos, López, Miguel, Contreras, Cristina · 2019 · International Journal of Molecular Sciences
12. EJE PRIZE 2018: A gut feeling about glucagon
    Knop, Filip K · 2018 · European Journal of Endocrinology
13. Altered glucose metabolism after bariatric surgery: What's GLP-1 got to do with it?
    Eric P. Smith, Georgina Polanco, Abid Yaqub, Marzieh Salehi · 2017 · Metabolism
14. GIP and the gut-bone axis – Physiological, pathophysiological and potential therapeutic implications
    Signe Stensen, Lærke S. Gasbjerg, Mads Marstrand Helsted, Bolette Hartmann, Mikkel Christensen, Filip Krag Knop · 2019 · Peptides
15. A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin
    Hiroshi Nomoto, Hideaki Miyoshi, Hajime Sugawara, Kota Ono, Shingo Yanagiya, Mayuko Oita, Akinobu Nakamura, Tatsuya Atsumi · 2017 · Diabetology & Metabolic Syndrome
16. Effects of meal and incretins in the regulation of splanchnic blood flow
    Jukka Koffert, Henri Honka, Jarmo Teuho, Saila P. Kauhanen, Saija A. M. Hurme, Riitta K Parkkola, Vesa Oikonen, Andrea Mari, Andreas Lindqvist, Nils Wierup et al. · 2017 · Endocrine Connections
17. Effects of endogenous GIP in patients with type 2 diabetes
    Signe Stensen, Lærke S. Gasbjerg, Liva S. L. Krogh, Kirsa Skov‐Jeppesen, Alexander H. Sparre‐Ulrich, M. Jensen, Flemming Dela, Bolette Hartmann, Tina Vilsbøll, Jens Juul Holst et al. · 2021 · European Journal of Endocrinology
18. Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes
    Angela Kim, Jakob Grunnet Knudsen, Joseph C. Madara, Anna Benrick, Thomas Hill, Lina Abdul Kadir, Joely A. Kellard, Lisa Mellander, Caroline Miranda, Haopeng Lin et al. · 2021 · eLife
19. Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future
    James P. Psaltis, J. Marathe, Mau T. Nguyen, Richard Le, Christina A. Bursill, Chinmay S. Marathe, Adam J. Nelson, Peter James Psaltis · 2024 · Medicinal Research Reviews
20. Time-restricted eating improves glycemic control and dampens energy-consuming pathways in human adipose tissue
    Lijun Zhao, Amy T. Hutchison, Bo Liu, Crystal Yates, Xiao Tong Teong, Gary Wittert, Campbell Henry Thompson, Leanne Nguyen, John Au, Emily N. C. Manoogian et al. · 2022 · Nutrition
21. Peptides in the regulation of glucagon secretion
    Daniel Bjørklund Andersen, Jens Juul Holst · 2021 · Peptides
22. GLP-1R Signaling and Functional Molecules in Incretin Therapy
    Wan, Wenwei, Qin, Qikai, Xie, Linshan, Zhang, Hanqing, Wu, Fan, Stevens, Raymond C., Liu, Yan · 2023 · Molecules
23. The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide
    Lærke S. Gasbjerg, METTE MARIE ROSENKILDE, Juris Jendrik Meier, Jens Juul Holst, Filip Krag Knop · 2023 · Diabetes Obesity and Metabolism
24. Establishment of a Refined Oral Glucose Tolerance Test in Pigs, and Assessment of Insulin, Glucagon and Glucagon-Like Peptide-1 Responses
    Elin Manell, Patricia Hedenqvist, Anna Christina Svensson, Marianne Jensen‐Waern · 2016 · PLoS ONE
25. Weight-centric treatment of type 2 diabetes mellitus
    Wissam Ghusn, Maria Daniela Hurtado, Andres J Acosta · 2022 · Obesity Pillars
26. A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine
    Chantal Mathieu, R. Ravi Shankar, Daniel Lorber, Guillermo E. Umpierrez, Fan Wu, Lei Xu, Gregory T. Golm, Melanie Latham, Keith D. Kaufman, Samuel S. Engel · 2015 · Diabetes Therapy
27. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
    Giuseppe Penno, Russo Russo, Stefano Del Prato · 2013 · Diabetes Metabolic Syndrome and Obesity
28. New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs
    Andreas P. Katsenos, Athena S. Davri, Yannis Vasileios Simos, Ilias P. Nikas, Chryssa Bekiari, Stavroula Α. Paschou, Dimitrios Peschos, Spyridon Konitsiotis, Patra Vezyraki, Konstantinos Ioannis Tsamis · 2021 · Expert Opinion on Investigational Drugs
29. GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
    Shilleh, Ali H., Viloria, Katrina, Broichhagen, Johannes, Campbell, Jonathan E., Hodson, David J. · 2024 · Peptides
30. Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
    Hwi Seung Kim, Chang Hee Jung · 2021 · International Journal of Molecular Sciences
31. Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials
    Permana, Hikmat, Yanto, Theo Audi, Hariyanto, Timotius Ivan · 2022 · Diabetes & Metabolic Syndrome: Clinical Research & Reviews
32. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects
    Tsuyoshi Yanagimachi, Yukihiro Fujita, Yasutaka Takeda, Jun Honjo, Hidemitsu Sakagami, Hiroya Kitsunai, Yumi Takiyama, Atsuko Abiko, Yuichi Makino, Timothy J. Kieffer et al. · 2017 · Molecular Metabolism
33. Molecular interactions of full-length and truncated GIP peptides with the GIP receptor – A comprehensive review
    Maria Buur Nordskov Gabe, Wijnand J. C. van der Velden, Florent Xavier Smit, Lærke S. Gasbjerg, METTE MARIE ROSENKILDE · 2019 · Peptides
34. Searching for the physiological role of glucose‐dependent insulinotropic polypeptide
    Holst, Jens Juul, Windeløv, Johanne Agerlin, Boer, Geke Aline, Pedersen, Jens, Svendsen, Berit, Christensen, Mikkel, Torekov, Signe, Asmar, Meena, Hartmann, Bolette, Nissen, Anne · 2016 · Journal of Diabetes Investigation
35. GIP’s involvement in the pathophysiology of type 2 diabetes
    Christensen, Mikkel B., Gasbjerg, Lærke S., Heimbürger, Sebastian M., Stensen, Signe, Vilsbøll, Tina, Knop, Filip K. · 2020 · Peptides
36. GPR142 prompts glucagon-like Peptide-1 release from islets to improve β cell function
    Hua V. Lin, Jingru Wang, Jie Wang, LI Wei-ji, Xuesong Wang, James T. Alston, Melissa K. Thomas, Daniel A. Briere, Samreen K. Syed, Alexander M. Efanov · 2018 · Molecular Metabolism
37. DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP–glucagon counterregulatory axis in mice
    Siri Malmgren, Bo Åhrén · 2015 · Diabetologia
38. Vasopressin receptors in islets enhance glucose tolerance, pancreatic beta-cell secretory function, proliferation and survival
    Shruti Mohan, R. Charlotte Moffett, Keith G. Thomas, Nigel Irwin, Peter R. Flatt · 2019 · Biochimie
39. Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
    Shizuka Kaneko · 2022 · touchREVIEWS in Endocrinology
40. Incretin and Islet Hormone Responses to Meals of Increasing Size in Healthy Subjects
    Alsalim, Wathik, Omar, Bilal, Pacini, Giovanni, Bizzotto, Roberto, Mari, Andrea, Ahrén, Bo · 2015 · The Journal of Clinical Endocrinology & Metabolism
41. Microenvironmental stimuli for proliferation of functional islet β-cells
    Hanan Alismail, Sha Jin · 2014 · Cell & Bioscience
42. Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
    Franco B. Folli, Giovanna Finzi, Roberto Manfrini, A. Galli, Francesca Casiraghi, Lucia Centofanti, Cesare Berra, Paolo Fiorina, Alberto M. Davalli, Stefano La Rosa et al. · 2023 · American Journal of Physiology-Endocrinology and Metabolism
43. Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors
    Deacon, Carolyn F · 2020 · Peptides
44. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)
    Frias, Juan P, De Block, Christophe, Brown, Katelyn, Wang, Hui, Thomas, Melissa K, Zeytinoglu, Meltem, Maldonado, Juan M · 2024 · The Journal of Clinical Endocrinology & Metabolism
45. GLP-1 Receptor Agonists in Pediatric and Adolescent Obesity
    Margaret A. Stefater‐Richards, Grace Jhe, Yanjia Jason Zhang · 2025 · PEDIATRICS
46. Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes
    Christophe E.M. De Block, Eveline Lia Dirinck, Ann A. Verhaegen, Luc F. Van Gaal · 2022 · Diabetes Obesity and Metabolism
47. Ectopic Expression of GIP in Pancreatic β-Cells Maintains Enhanced Insulin Secretion in Mice With Complete Absence of Proglucagon-Derived Peptides
    Ayako Fukami, Yusuke Seino, Nobuaki Ozaki, Michiyo Yamamoto, Chisato Sugiyama, Eriko Sakamoto-Miura, Tatsuhito Himeno, Yoshiko Takagishi, Shin Tsunekawa, Safina Ali et al. · 2012 · Diabetes
48. Therapeutic Effects of Endogenous Incretin Hormones and Exogenous Incretin-Based Medications in Sepsis
    Faraaz Ali Shah, Hussain Mahmud, Teresa Gallego‐Martin, Michael J. Jurczak, Christopher Paul O'Donnell, Bryan J. McVerry · 2019 · The Journal of Clinical Endocrinology & Metabolism
49. Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects
    Mia Demant, Jonatan Ising Bagger, Malte Palm Suppli, Asger Lund, Mette Gyldenløve, Katrine Bagge Hansen, Kristine Juul Hare, Mikkel Christensen, David Peick Sonne, Jens Juul Holst et al. · 2018 · Metabolic Syndrome and Related Disorders
50. Repositioning the Alpha Cell in Postprandial Metabolism
    KIMBERLEY M. EL, Megan E. Capozzi, Jonathan E. Campbell · 2020 · Endocrinology
51. The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects
    Nicolai Alexander Rhee, Signe Harring Østoft, Jens Juul Holst, Carolyn Fiona Deacon, Tina Vilsbøll, Filip Krag Knop · 2014 · European Journal of Endocrinology
52. Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut
    Nadya M. Morrow, Arianne Morissette, Erin E. Mulvihill · 2024 · Peptides
53. Effect of gut hormones on bone metabolism and their possible mechanisms in the treatment of osteoporosis
    Hongyu Liu, Huimin Xiao, Sufen Lin, Huan Zhou, Yizhao Cheng, Baocheng Xie, Daohua Xu · 2024 · Frontiers in Pharmacology
54. Altered desensitization and internalization patterns of rodent versus human glucose‐dependent insulinotropic polypeptide (GIP) receptors. An important drug discovery challenge
    Lærke S. Gasbjerg, Rasmus Syberg Rasmussen, Adrian Dragan, Peter Lindquist, Josefine Ulrikke Melchiorsen, Tomasz Maciej Stępniewski, Sine P. Schiellerup, Esther Karen Tordrup, Sarina Gadgaard, Hüsün Sheyma Kizilkaya et al. · 2024 · British Journal of Pharmacology
55. Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion
    Linda Ahlkvist, K Brown, Bo Åhrén · 2013 · Endocrine Connections
56. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin
    Anja Schweizer, James Edward Foley, Wolfgang Kothny, Bo Åhrén · 2013 · Vascular Health and Risk Management
57. Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome
    Κλεοπάτρα Αλεξιάδου, Tricia Tan · 2020 · Current Diabetes Reports
58. Glucose-Dependent Insulinotropic Polypeptide—A Postprandial Hormone with Unharnessed Metabolic Potential
    Nunzio Guccio, Fiona Mary Gribble, Frank M. Reimann · 2022 · Annual Review of Nutrition
59. Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1–30) expression is upregulated in diabetes and PEGylated GIP(1–30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice
    Tsuyoshi Yanagimachi, Yukihiro Fujita, Yasutaka Takeda, Jun Honjo, Kuralay K. Atageldiyeva, Yumi Takiyama, Atsuko Abiko, Yuichi Makino, Timothy J. Kieffer, Masakazu Haneda · 2015 · Diabetologia
60. Effects of DPP ‐4 inhibitor linagliptin and GLP ‐1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open‐label, 2‐arm parallel comparative, exploratory trial
    Daisuke Yabe, Takashi Eto, Masanari Shiramoto, Shin Irie, Kenta Murotani, Yusuke Seino, Hitoshi Kuwata, Takeshi Kurose, Susumu Seino, Bo Åhrén et al. · 2016 · Diabetes Obesity and Metabolism
61. Gastrointestinal Hormones ☆
    Fiona Mary Gribble, Frank M. Reimann, Geoffrey P. Roberts · 2018 · Elsevier eBooks
62. Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?
    Alexander D. Kokkinos, Dimitrios Tsilingiris, Carel Wynand le Roux, Francesco Rubino, Christos Socrates Mantzoros · 2019 · Metabolism
63. The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review
    Zhao Liu, Shanshan Yu, Xinyan Jin, Luguang Sheng, Mai Re YanMu Rouzi, Jie Gao, Jun Lü, Tao Lei · 2025 · Drug Design Development and Therapy
64. Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes
    Silvio E. Inzucchi, Michael Albrecht Nauck, Uwe Hehnke, Hans Juergen Woerle, Maximilian von Eynatten, Robert R. Henry · 2015 · Diabetes Obesity and Metabolism
65. Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes
    Eleonora Grespan, Toni Giorgino A, Andrea Natali, Ele Ferrannini, Andrea Mari · 2020 · Metabolism
66. Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor
    Jennifer D. Koenitzer, Shreya Pramanick, Qi Pan, Robert Augustin, Sebastian Bandholtz, William D. Harriman, Shelley Mettler Izquierdo · 2017 · mAbs
67. Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data
    Ioanna A. Anastasiou, Georgia Argyrakopoulou, Μaria Dalamaga, Alexander D. Kokkinos · 2025 · Current Obesity Reports
68. Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes
    Mikkel Christensen, Asger Lund, Niklas Rye Jørgensen, Jens Juul Holst, Tina Vilsbøll, Filip Krag Knop · 2020 · Journal of the Endocrine Society
69. Effects of GLP-1 and GIP on Islet Function in Glucose-Intolerant, Pancreatic-Insufficient Cystic Fibrosis
    Sarah C. Nyirjesy, Amy J. Peleckis, Jack N. Eiel, Kathryn Gallagher, Andriana Doliba, Abigail Tami, Anneliese J. Flatt, Diva D. De León, Denis Hadjiliadis, Saba Sheikh et al. · 2022 · Diabetes
70. Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators
    David García‐Vega, José Ramón González‐Juanatey, Sonia Eirás · 2022 · International Journal of Molecular Sciences
71. Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis
    Ruifang Guan, Qing Yang, Xiaolei Yang, Wandi Du, Xuening Li, Guo Ma · 2022 · Frontiers in Pharmacology
72. Prior Exercise and Postprandial Incretin Responses in Lean and Obese Individuals
    Timothy D. Heden, Ying Liu, Monica L. Kearney, Young‐Min Park, Kevin C. Dellsperger, Tom R Thomas, Jill A. Kanaley · 2013 · Medicine & Science in Sports & Exercise
73. Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice
    Andrea Tura, Giovanni Pacini, Yuchiro Yamada, Yutaka Seino, Bo Åhrén · 2018 · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
74. Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture
    Holst, Jens Juul · 2021 · Diabetes
75. The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review
    Dai Yamanouchi · 2025 · International Journal of Molecular Sciences
76. Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy
    Bernard Chong Eu Khoo, Tricia Tan · 2020 · Journal of Endocrinology
77. Molecular Pharmacology of the Incretin Receptors
    Suleiman Al‐Sabah · 2015 · Medical Principles and Practice
78. Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability
    Chang Yu Pan, Wang · 2013 · Therapeutics and Clinical Risk Management
79. Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose
    Henrik Maagensen, Anders Ellekaer Junker, Niklas Rye Jørgensen, Lise Lotte Gluud, Filip Krag Knop, Tina Vilsbøll · 2018 · The Journal of Clinical Endocrinology & Metabolism
80. GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology
    METTE MARIE ROSENKILDE, Peter Lindquist, Hüsün Sheyma Kizilkaya, Lærke S. Gasbjerg · 2024 · Peptides
81. Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance
    Song-Yan Wang, Lauren Z. Oestricker, M. Wallendorf, K. Sterl, J. Dunai, C. Kilpatrick, B. Patterson, Dominic N. Reeds, B. Wice · 2018 · PLoS ONE
82. The Effect of Exogenous Glucose-Dependent Insulinotropic Polypeptide in Combination With Glucagon-Like Peptide-1 on Glycemia in the Critically Ill
    Michael Y. Lee, Jonathan D. Fraser, Marianne J. Chapman, Krishnaswamy Sundararajan, Mahesh Michael Umapathysivam, Matthew J. Summers, Antony V Zaknic, Christopher Keith Rayner, Juris Jendrik Meier, Michael Horowitz et al. · 2013 · Diabetes Care
83. Combination Therapy With DPP-4 Inhibitors and Insulin in Patients With Type 2 Diabetes Mellitus: What Is the Evidence?
    Bernard H. Charbonnel, Anja Schweizer, Sylvie Dejager · 2013 · Hospital Practice
84. Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan
    Anja Schweizer, S. Halimi, Sylvie Dejager · 2013 · Vascular Health and Risk Management
85. Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study
    P. Kar, Caroline E. Cousins, Christopher E. Annink, Karen L. Jones, Marianne J. Chapman, Juris Jendrik Meier, Michael Albrecht Nauck, Michael Horowitz, Adam M. Deane · 2015 · Critical Care
86. Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study
    Ronan Roussel, Santiago Durán-Garcia, Yilong Zhang, Suneri Shah, Carolyn Darmiento, R. Ravi Shankar, Gregory T. Golm, Raymond L. H. Lam, Edward A. O’Neill, Ira Gantz et al. · 2018 · Diabetes Obesity and Metabolism
87. Periodontitis affects glucoregulatory hormones in severely obese individuals
    Anna Solini, Jean E. Suvan, Eleonora Santini, Stefano Gennai, Marta Seghieri, Stefano Masi, Morena Petrini, Francesco D’Aiuto, Filippo Graziani · 2018 · International Journal of Obesity
88. Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes
    Johan Farngren, Bo Åhrén · 2019 · Metabolism
89. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males
    Gabriella A. Heruc, Michael Horowitz, Carolyn Fiona Deacon, Christine Feinle‐Bisset, Christopher Keith Rayner, Natalie D. Luscombe‐Marsh, Tanya J. Little · 2014 · American Journal of Physiology-Endocrinology and Metabolism
90. Differential Effects of Oral and Intravenous Lipid Administration on Key Molecules Related to Energy Homeostasis
    Maria T. Vamvini, Ole‐Petter R. Hamnvik, Ayse Sahin-Efe, Anna Gavrieli, Fadime Dincer, Olivia M. Farr, Christos Socrates Mantzoros · 2016 · The Journal of Clinical Endocrinology & Metabolism
91. Bariatric Surgery Enhances Splanchnic Vascular Responses in Patients With Type 2 Diabetes
    Henri Honka, Jukka Koffert, Saila P. Kauhanen, Jarmo Teuho, Saija A. M. Hurme, Andrea Mari, Andreas Lindqvist, Nils Wierup, Leif Groop, Pirjo Nuutila · 2017 · Diabetes
92. An incretin-based tri-agonist promotes superior insulin secretion from murine pancreatic islets via PLC activation
    Noushafarin Khajavi, Brian Finan, Oliver Kluth, Timo D. Müller, Stefan Mergler, Angela Schulz, Gunnar Kleinau, Patrick Scheerer, Annette Schürmann, Thomas W. Gudermann et al. · 2018 · Cellular Signalling
93. Proglucagon-derived peptides: human physiology and therapeutic potential
    Lærke S. Gasbjerg, Casper K. Nielsen, Malte Palm Suppli, Magnus F.G. Grøndahl, Jens Juul Holst, Filip Krag Knop, Palle Bekker Jeppesen, Asger Lund · 2025 · Physiological Reviews
94. Distinct Identity of GLP-1R, GLP-2R, and GIPR Expressing Cells and Signaling Circuits Within the Gastrointestinal Tract
    Nadya M. Morrow, Antonio A. Hanson, Erin E. Mulvihill · 2021 · Frontiers in Cell and Developmental Biology
95. Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
    Xianxian Huang, Jing Liu, Guangquan Peng, Mingyue Lu, Zhongbo Zhou, Neng Jiang, Zhiming Yan · 2024 · Journal of Endocrinology
96. Effects of sitagliptin on counter‐regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double‐blind placebo‐controlled crossover study
    Josefine E. Schopman, Joost B.L. Hoekstra, Brian M. Frier, Mariëtte T. Ackermans, Jeroen J.J. de Sonnaville, Aline M.E. Stades, Rolf Zwertbroek, Bolette Hartmann, Jens Juul Holst, Filip Krag Knop et al. · 2015 · Diabetes Obesity and Metabolism
97. Vildagliptin and caloric restriction for cardioprotection in pre-diabetic rats
    Pongpan Tanajak, Hiranya Pintana, Natthaphat Siri‐Angkul, Juthamas Khamseekaew, Nattayaporn Apaijai, Siriporn Chaisin Chattipakorn, Nipon Chattipakorn · 2016 · Journal of Endocrinology
98. Post-pancreatitis diabetes mellitus: investigational drugs in preclinical and clinical development and therapeutic implications
    Maxim S. Petrov · 2021 · Expert Opinion on Investigational Drugs
99. Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
    Berthold Hocher, Karoline von Websky, Christoph Reichetzeder · 2013 · Vascular Health and Risk Management
100. Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic Receptors
     Noushafarin Khajavi, Heike Biebermann, Matthias H. Tschöp, Richard D. DiMarchi · 2017 · Endocrine development